Whilst characterised by low frequency of anti-tumour responses, single-agent anti-CTLA-4 therapy leads to long-term survivorship in ~20% of patients, providing evidence of long-lasting immune reconstitution [104]. The gene discussed is CTLA4; the disease is neoplasm.